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Eosinophilic myocarditis is a life-threatening complication of
eosinophilic syndromes including eosinophilic granulomatosis
with polyangiitis (EGPA), undefined complex hypereosinophilic
syndrome (HES), and drug rash with eosinophilia and systemic
symptoms (DRESS) syndrome. The in-hospital death rate for eosin-
ophilic myocarditis due to any cause is about 20%,1 and is as high as
50% in its acute necrotizing form associated with DRESS.2 Conven-
tional therapies including high-dose glucocorticoids and other im-
munosuppressants have variable efficacy and substantial toxic
effects.1 Dilated cardiomyopathy is a frightening sequela but its
incidence is unknown.
Recent studies investigated anti-interleukin 5 (mepolizumab)
or anti-interleukin 5 receptor (benralizumab) monoclonal anti-
bodies for the treatment of EGPA or HES.3e6 One double-blind
study of mepolizumab vs placebo in patients with relapsing or
refractory EGPA on steroid therapy reported more frequent and
more prolonged responses in the mepolizumab group, but the
response rate of cardiomyopathy was not addressed.3 A subse-
quent study in patients with HES reported overall clinical efficacy
of mepolizumab but poor responses in patients with cardiac
involvement.4 In fact, only partial response of cardiologic mani-
festations was observed in 45% of patients, and no response in
50%; importantly, patients treated with mepolizumab had a
long duration of disease prior therapy (median 4.6 years). Two
studies investigated the efficacy of benralizumab. One case report
described a good clinical response and decrease of MPO-ANCA
titer in an EGPA patient without cardiac involvement.5 In a
double-blind, placebo-controlled study,6 patients with HES
were treated with monthly injections of benralizumab (30 mg)
up to week 48; although clinical and hematologic responses
were observed in 74% of cases, in the three patients with long-
lasting cardiac involvement there was no cardiologic response.
Thus, both randomized studies in HES4,6 suggest that cardiac
involvement is unlikely to respond to anti-interleukin 5 treat-
ment unless treatment is started promptly before extensive
fibrosis and irreversible myocardial damage develop. Here we
describe a patient with EGPA complicated by eosinophilic
myocarditis that had an excellent response to early treatment
with benralizumab.Peer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).This 19-year-old male had an irrelevant clinical history and
presented acutely with fatigue, moderate dyspnea, urticaria,
asthma refractory to budesonide/formoterol fumarate hydrate
inhaler (one inhalation at a time, twice a day), bloody diarrhea
due to histologically proven eosinophilic colitis, axonal sensory
motor neuropathy, and eosinophilia up to 13,470 cells/mL. Myeloid
and lymphocytic HES were excluded by absence of PDGFRa,
PDGFRb, FGFR1 and ABL rearrangements, bone marrow biopsy
and lymphocyte immunophenotyping; antineutrophil cytoplasmic
antibodies (ANCA) were negative. Thus, a diagnosis of ANCA-
negative EGPA was made. Echocardiography and cardiac MRI
revealed reduced global myocardial function (ejection fraction
40%) (Supplementary Table 1); tissue MRI showed diffuse suben-
docardial inflammatory edema and fibrosis (Fig. 1). Holter moni-
toring revealed numerous ectopic ventricular beats organized in
couplets. An endomyocardial biopsy confirmed eosinophilic
myocarditis with endomyocardial fibrosis and an eosinophilic in-
flammatory infiltrate. Beside ACE inhibitors, beta-blockers and
aspirin as cardiovascular therapy, he was treated with high-dose
glucocorticoid (methylprednisolone 1 mg/kg body weight) for
two weeks but developed severe cushingoid features with high
blood pressure. Despite achieving a discrete response of colitis
he obtained poor control of asthma, peripheral neuropathy and
cardiopathy. Alternative treatments with intravenous cyclophosfa-
mide, rituximab or high-dose intravenous immunoglobulin ther-
apy (IVIG) were initially ruled out because of known toxicities
(cyclophosfamide) and poor evidence of efficacy for eosinophilic
myocarditis.1,7
Prednisone was gradually tapered to 5 mg/day after an addi-
tional month when hewas switched to benralizumab 30mg subcu-
taneously according to the schedule approved by the European
Medicines Agency for refractory asthma that is threemonthly injec-
tions followed by one injection every two months.
The absolute eosinophil count remained 0 during the phase of
monthly injections, but circulating eosinophils reappeared,
although remaining below the upper normal limit (500 cells/mL),
when benralizumab was given at two-month intervals; basophils
remained stable throughout therapy (Fig. 2). Good asthma control
was achieved, neuropathy improved and a colon biopsy done at
month 7 of benralizumab therapy showed regression of the eosin-
ophilic infiltrate. More importantly, echocardiographic examina-
tion showed that the ejection fraction had increased to 60% aftervier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 2. Absolute counts of circulating eosinophils (circles) and basophils (triangles)
during treatment. The gray area denotes glucocorticoid therapy (methylprednisolone
1 mg/kg body weight), and arrows denote benralizumab (30 mg) injections.
Fig. 1. Patient's cardiac MRI before and 12 months after benralizumab therapy. Pre-
contrast T2-weighted-STIR four-chamber (A, B) and short axis views (C, D) showing
subendocardial and midwall myocardial hyperintensity compatible with acute edema
(arrows) before benralizumab (A, C) and normal signal of the myocardial wall after 12
months (B, D). Post-contrast T1-weighted IR four-chamber (E, F) and short axis (G, H)
views showing subendocardial late gadolinium enhancement (LGE) of the septal wall
and papillary muscles, indicative of subendocardial fibrosis (arrows) before benralizu-
mab (E, G) and persisting after 12 months (F, H).
Letter to the Editor / Allergology International 69 (2020) 483e484484two months of benralizumab therapy and maintained throughout
the follow-up (Supplementary Table 1). A cardiac MRI done after
12 months of benralizumab therapy showed a normal ejection frac-
tion, regression of inflammatory edema, but no changes of suben-
docardial fibrosis (Fig. 1).
Taking into account the high in-hospital mortality with conven-
tional therapy,1 the risk for rapid irreversible myocardial damage,
and the lack of response of cardiopathy when anti-interleukin 5
treatment is delayed,4,6 this case endorses early treatment with
benralizumab as a first line option for eosinophilic myocarditis
associated with hypereosinophilic syndromes.Acknowledgement
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